Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Core Insights - Alterity Therapeutics has received positive regulatory feedback from the FDA regarding its Phase 3 development program for ATH434 in Multiple System Atrophy (MSA) [1][2] - The Type C Meeting with the FDA confirmed alignment on clinical pharmacology and non-clinical development elements, which is crucial for initiating the Phase 3 pivotal trial [2][3] - The company aims to achieve agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting scheduled for mid-2026 [3] Company Overview - Alterity Therapeutics is focused on developing disease-modifying therapies for neurodegenerative diseases, particularly MSA and related Parkinsonian disorders [4] - The lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial and positive results in an open-label Phase 2 trial for advanced MSA [4] - The company operates from Melbourne, Australia, and San Francisco, California, and has a drug discovery platform aimed at creating patentable compounds for neurological diseases [4]